Sublingual Immunotherapy (SLIT) in Atopic Dermatitis

The current evidence regarding the usefulness of injection (subcutaneous) immunotherapy (SCIT) in atopic dermatitis is inconclusive.

Sublingual immunotherapy (SLIT) generally has an established safety profile in children and its effect was studied in this double-blind, controlled trial of patients (aged 5-16 years) with atopic dermatitis sensitized to dust mites.

SLIT or placebo was given for 18 months and 48 children completed the study. The difference from baseline was calculated using the Scoring of Atopic Dermatitis (SCORAD) and was significant in favor of the SLIT group starting from month 9.

The difference was noted only in children with a mild-moderate disease but not in those with severe atopic dermatitis. SLIT had to be stopped in 2 children because of exacerbation of dermatitis.

According to the study authors, SLIT to dust mite may improve mild-moderate atopic dermatitis and could be useful as an additional therapeutic tool.

Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: A randomized, double-blind, placebo-controlled study. Giovanni B. Pajno et al. JACI, Volume 120, Issue 1, Pages 164-170 (July 2007).
Talking Points on Sublingual Immunotherapy (SLIT) for Physicians Practicing in the United States. ACAAI.
Image source: Wikipedia, public domain.

No comments:

Post a Comment